This week’s topics include prehospital ticagrelor in STEMI, ivabradine in stable CAD without clinical HF, FFR-guided PCI for stable CAD, and more.
New Observations on Saxagliptin (15 Sep 2014)Benjamin Scirica, MD MPH
Benjamin Scirica discusses his study group’s new analysis of data from the SAVOR-TIMI 53 randomized, placebo-controlled trial of saxagliptin in patients with type 2 diabetes.
How to Ace Your Fellowship Interview (15 Sep 2014)Ethan J Weiss, M.D.
The following compilation of fellowship interview tips was originally published on Twitter between August 15th and 18th by Ethan Weiss, a cardiologist with 13 years of experience interviewing fellowship applicants. Matthew Pirotte also supplied this helpful graph categorizing potential applicants. 1. Prepare like you are interviewing for a job. You are. Know who you are meeting and who you want to meet with. 2. Learn the strengths and weaknesses of the institution you are visiting and use the information to help you. 3. Your choice of a research mentor is the… Continue Reading
Boback Ziaeian discusses his observational study exploring the benefits of guideline-recommended cardiac resynchronization therapy and ICD therapy in heart failure patients, according to race and ethnicity.
Is This Trial Ethical? (11 Sep 2014)CardioExchange Editors, Staff
Does the need for a new placebo-controlled trial of epinephrine in cardiac arrest justify questionable consent procedures?
This week’s topics include the PARADIGM-HF trial, sham controls in medical-device trials, the efficacy of β blockers in patients with heart failure and atrial fibrillation, and more.
Perspectives on PARADIGM-HF (5 Sep 2014)CardioExchange Editors, Staff
The Editors present a distillation of reader comments on a popular post.
FAME 2 at 2 Years: Better with Time? (3 Sep 2014)CardioExchange Editors, Staff
The CardioExchange editors ask whether the 2-year findings from FAME 2 are more compelling than the 7-month findings.
Let’s Take a Close Look at PARADIGM-HF (1 Sep 2014)Vinay Prasad, MD MPH
Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.
This week’s topics include aortic valve stenosis, presenting the benefits of PCI to patients, and more.